Application of Tyrosine Kinase Inhibitor to GIST Patients Seiichi Hirota 1 1Division of Surgical Pathology, Osaka University Medical Hospital Keyword: GIST , imatinib mesylate , c-kit 遺伝子 , PDGFRα 遺伝子 , 機能獲得性突然変異 pp.683-687
Published Date 2004/4/24
DOI https://doi.org/10.11477/mf.1403100508
  • Abstract
  • Look Inside
  • Reference

 Imatinib mesylate is allowed to be applied to KIT-positive GISTs in Japan, but it should not be indiscriminately used for surgically treatable GISTs. Since the effect of Imatinib depends on the types of mutations of c-kit gene or PDGFR αgene, an analysis of the mutation of these genes is essential to predict the patient's response to the drug. Use of Imatinib as adjuvant therapy is now being studied, so the results will give information whether its use as adjuvant therapy is required or not. In patients with regrowth of GISTs after Imatinib administration, the drug could be continuously applied if the resistant clone has been successfully removed.

 1) Division of Surgical Pathology, Osaka University Medical Hospital, Suita, Japan

Copyright © 2004, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1219 印刷版ISSN 0536-2180 医学書院